NYSE •
Healthcare •
Biotechnology •
Quote as of 05/27/2026 15:48
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization732.06 mln
Float23.95 mln
Earnings Date08/19/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
35.13
Transformational upside
Relative Strength
1
/ 100
Severely lagging
Debt / Equity
0.09
Debt-free
ROE
-48.34
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Alto Neuroscience is a drug development company based in Mountain View, California, focused on creating new treatments for brain and mental health conditions. The company has several medications in various stages of clinical testing, targeting conditions such as bipolar depression, major depressive disorder, schizophrenia-related cognitive impairment, and Parkinson's disease. Founded in 2019, Alto Neuroscience is working to advance these experimental drugs through clinical trials toward potential approval and patient use.
